Last updated 44 hours ago

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

276 patients around the world
Available in Chile
AbbVie
3Research sites
276Patients around the world

This study is for people with

Crohn's disease

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Biopsy-confirmed diagnosis of CD for at least 3 months prior to Baseline.
Participant meets the following disease activity criteria.
Moderate to severe CD as assessed by CDAI.
Endoscopic evidence of mucosal inflammation as documented by a SES-CD.
Participant has demonstrated intolerance, loss of response or inadequate response to conventional or advanced therapies for CD.
Participants with a current diagnosis of ulcerative colitis or indeterminate colitis.
Participants with unstable doses of concomitant Crohn's disease therapy.
Participants with prior exposure to p19 inhibitors.
Participants with complications of Crohn's disease.
Participants having an ostomy or ileoanal pouch.

Sites

Clínica Dermacross S.A. - Vitacura - Santiago
Clínica Dermacross S.A. - Vitacura - Santiago
Recruiting
Av. Manquehue Norte 2051 C, Vitacura, Metropolitana, 7640881
Clínica Universidad de los Andes
Recruiting
Av Plaza 2501, Las Condes, Región Metropolitana, Santiago
Espacio EME
Recruiting
Av. Ricardo Lyon 2911, Ñuñoa Región Metropolitana
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy